[go: up one dir, main page]

AU2001266604A1 - Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders - Google Patents

Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Info

Publication number
AU2001266604A1
AU2001266604A1 AU2001266604A AU6660401A AU2001266604A1 AU 2001266604 A1 AU2001266604 A1 AU 2001266604A1 AU 2001266604 A AU2001266604 A AU 2001266604A AU 6660401 A AU6660401 A AU 6660401A AU 2001266604 A1 AU2001266604 A1 AU 2001266604A1
Authority
AU
Australia
Prior art keywords
rank ligand
treatment
monoclonal antibodies
mediated disorders
antibodies useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266604A
Other languages
English (en)
Inventor
Simon M. Blake
Raymond W. Sweet
Alexander H. Taylor
Trevor A. Wattam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of AU2001266604A1 publication Critical patent/AU2001266604A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001266604A 2000-05-26 2001-05-24 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders Abandoned AU2001266604A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20762800P 2000-05-26 2000-05-26
US60207628 2000-05-26
PCT/US2001/016865 WO2001091793A1 (fr) 2000-05-26 2001-05-24 Anticorps monoclonaux contre le ligand rank, utilises pour le traitement d'etats pathologiques lies au ligand rank

Publications (1)

Publication Number Publication Date
AU2001266604A1 true AU2001266604A1 (en) 2001-12-11

Family

ID=22771340

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266604A Abandoned AU2001266604A1 (en) 2000-05-26 2001-05-24 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Country Status (6)

Country Link
US (1) US20030215450A1 (fr)
EP (1) EP1283721A4 (fr)
JP (1) JP2003534022A (fr)
AU (1) AU2001266604A1 (fr)
HK (1) HK1054316A1 (fr)
WO (1) WO2001091793A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
ES2208145T3 (es) 2000-09-22 2007-12-16 Immunex Corporation Ensayos de seleccion para agonistas o antagonistas del receptor activador de nf-kb.
WO2002095012A1 (fr) * 2001-05-18 2002-11-28 Smithkline Beecham Corporation Anticorps monoclonaux a ligands anti-rank convenant au traitement de troubles induits par des ligands rank
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ES2675735T3 (es) 2001-06-26 2018-07-12 Amgen Inc. Anticuerpos para OPGL
US7935338B2 (en) 2001-12-11 2011-05-03 University Of Massachusetts Antibodies to treat cancer
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US7615211B2 (en) * 2004-02-09 2009-11-10 Cbr Institute For Biomedical Research, Inc. CD70 inhibition for the treatment and prevention of inflammatory bowel disease
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
WO2009105934A1 (fr) * 2008-02-27 2009-09-03 上海先导药业有限公司 Anticorps monoclonal anti-rankl humain
CN101970493A (zh) 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
CN102741286B (zh) * 2010-03-26 2013-12-25 刘庆法 以pae技术开发的抗人rankl单抗及其应用
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
EP3447075B1 (fr) 2015-05-15 2023-08-09 The General Hospital Corporation Anticorps antagonistes de la superfamille du récepteur du facteur de nécrose contre les tumeurs
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
AU2017263833B2 (en) 2016-05-13 2023-08-03 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
EA201990557A1 (ru) * 2016-10-28 2019-09-30 Эли Лилли Энд Компани Анти-rankl антитела и их применение
CN120227454B (zh) * 2025-06-03 2025-09-02 深圳泰华赛尔生物科技有限公司 干细胞外泌体与在制备防治宠物骨关节疾病药物中应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
EP1514934B1 (fr) * 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Protéine de liaison biosynthétique pour marqueur de cancer
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
WO1998028424A2 (fr) * 1996-12-23 1998-07-02 Immunex Corporation Activateur du recepteur de nf-kappab, recepteur membre de la superfamille des recepteurs de tnf
WO1999029865A2 (fr) * 1997-12-12 1999-06-17 The Rockefeller University Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation
WO2000015807A1 (fr) * 1998-09-15 2000-03-23 M & E Biotech A/S Procede de regulation negative de l'activite des ligands d'osteoprotegerine

Also Published As

Publication number Publication date
EP1283721A1 (fr) 2003-02-19
HK1054316A1 (zh) 2003-11-28
US20030215450A1 (en) 2003-11-20
WO2001091793A1 (fr) 2001-12-06
EP1283721A4 (fr) 2004-07-07
JP2003534022A (ja) 2003-11-18

Similar Documents

Publication Publication Date Title
AU2001266604A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001288342A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
EP1482972A4 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
EP2940044B8 (fr) Anticorps anti-tnf alpha pour l'utilisation dans la therapie
TWI365193B (en) Human antibodies that bind human il-12 and methods for producing
PL398596A1 (pl) Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α
HUE064610T2 (hu) Új anti-IL 13 antitestek és alkalmazásaik
SG2013096847A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU5441000A (en) Human monoclonal antibody
AU2002351374A8 (en) Antibodies to treat cancer
EP1389233A4 (fr) Anticorps monoclonaux a ligands anti-rank convenant au traitement de troubles induits par des ligands rank
AU2002309645A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001281099A1 (en) Production of human monoclonal antibodies
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
HK1052187A (en) Antibodies that bind human interleukin-18 and methods of making and using
AU2002320072A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
AU2002238858A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
WO2001092331A8 (fr) Compositions et methodes de traitement de maladies d'origine immune
AU2002316887A1 (en) Anti-ige antibody to treat ocular allergies
HK1045699A (en) Human antibodies that bind human il-12 and methods for producing
IL135025A0 (en) Monoclonal antibodies to the human ldl receptor, their production and use